JP Morgan 2025: Radiopharmaceuticals M&A fuels Telix’s busy year

Following a year thick with acquisitions across the radiopharmaceutical supply chain, Telix Pharmaceuticals has announced a 55% year-on-year revenue increase in 2024.

CEO Christian Behrenbruch described the Australian company’s success in a presentation at the 2025 JP Morgan Healthcare Conference on 15 January in San Francisco. After a flurry of acquisitions, Behrenbruch announced Telix superseded its 2024 revenue guidance, generating $517m as its stock continues to rise.